Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM313 in Relapsed/Refractory Primary Immune Thrombocytopenia
NCT05694767Phase 2Completed
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jan 2023
- Primary completion
- Dec 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cm313 in immune thrombocytopenia (ITP), sponsored by Institute of Hematology and Blood Diseases Hospital. Started Jan 2023; status: completed.
02
Drugs
cm313
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT05694767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05694767.